您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Bomedemstat HCl
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Bomedemstat HCl
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Bomedemstat HCl图片
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
理化性质和储存条件

Molecular Formula: C28H35ClFN7O2;

Molecular Weight: 556.07

Synonym: IMG-7289 HCl; Bomedemstat HCl; IMG7289; IMG 7289; Bomedemstat hydrochloride;

Chemical Name: N-[(1S)-4-[[(1R,2S)-2-(4-Fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)benzamide dihydrochloride

InChi Key: PPKDUCDLYRHGFX-DVNXTAPYSA-N

InChi Code: InChI=1S/C28H34FN7O2.2ClH/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36;;/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37);2*1H/t24-,25-,26+;;/m0../s1

SMILES Code: O=C(N[C@H](C(N1CCN(C)CC1)=O)CCCN[C@H]2[C@H](C3=CC=C(F)C=C3)C2)C4=CC=C(N5N=NC=C5)C=C4.[H]Cl.[H]Cl


    In VitroBomedemstat (IMG-7289) selectively inhibits proliferation and induced apoptosis of JAK2V617F cells by concomitantly increasing expression and methylation of p53, and, independently, the pro-apoptotic factor PUMA and by decreasing the levels of its antiapoptotic antagonist BCL-XL[1].  Bomedemstat (25  nM, 50 nM) and Ruxolitinib (175 nM) synergize in inhibiting JAK2V617F-driven proliferation[1]. Bomedemstat (50 and 100 nM) exerts a pro-apoptotic effect on 3 key regulators of programmed cell death, TP53, BCL-XL, and PUMA[1]. Cell Viability Assay[1] Cell Line: The human cell lines SET-2 (ATCC 608) and HEK293 Concentration: 25  nM, 50 nM Incubation Time: 96 hours Result: 25 nM alone significantly reduced colony formation. Western Blot Analysis[1] Cell Line: SET-2 cells Concentration: 50 and 100 nM Incubation Time: Result: Decreased levels of the antiapoptotic protein BCL-XL and increased levels of the pro-apoptotic protein PUMA.
    In VivoOnce-daily treatment with Bomedemstat (IMG-7289; 45 mg/kg) normalizes or improves blood cell counts, reduces spleen volumes, restores normal splenic architecture, and reduces bone marrow fibrosis[1]. Animal Model: Mx1cre-Jak2V617F mice[1] Dosage: 45  mg/kg Administration: Administered daily by oral gavage for either 14, 42, or 56 consecutive days Result: In this Mx-Jak2V617F model of myeloproliferative neoplasm (MPN), mice developed severe splenomegaly (up to 10-fold increase in spleen weight). Splenic architecture was completely destroyed, eliminating demarcation of the white and red pulp. Treatment significantly reduced splenomegaly with a few treated mice normalizing their spleen weight. Remarkably, the 56-day course led to partial restoration of lymph follicles and spleen architecture by histological examination.